A widely-shared case series claiming a veterinary dewormer treats cancer was retracted — for an undisclosed conflict of interest, not disproven data

Content format: Myth vs. Evidence

Important context

Non-causation (observational data cannot prove cause and effect): This uncontrolled, self-reported case series of three patients cannot establish that fenbendazole caused their outcomes — all three were also receiving standard cancer treatment at the same time, and the underlying paper has since been retracted.

A case series titled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients,” published in the peer-reviewed journal Case Reports in Oncology in 2025 (DOI 10.1159/000546362, PMID 40605964), described three patients with stage IV cancers (breast, prostate, and melanoma) who self-administered fenbendazole — an over-the-counter veterinary dewormer with no FDA approval for human use of any kind, let alone cancer treatment — alongside their standard treatments, and reported that all three went into remission. The article circulated widely online, including on social media, as purported evidence that a cheap, unregulated dewormer “cures cancer.” On January 21, 2026, the journal’s Editor, Dr. Maurie Markman, retracted the article (retraction statement: DOI 10.1159/000549387, PMID 41574240) after it came to light that the lead author had an undeclared financial conflict of interest — specifically, that he offers paid clinical services related to treating cancer patients with fenbendazole, a fact not disclosed in the article’s conflict-of-interest statement. The retraction notice is explicit that the concern is the undisclosed conflict of interest, not that the underlying case data was found to be fabricated or incorrect; the retraction nonetheless means the paper is no longer valid, citable evidence. No clinical trial has ever tested whether fenbendazole treats cancer in humans, and case reports of self-administered, uncontrolled treatment combinations of this kind cannot establish that fenbendazole caused these three patients’ outcomes, since all three were also receiving conventional cancer treatment at the same time.

What This Means

A peer-reviewed case series describing three patients who self-administered fenbendazole (a veterinary dewormer, not an approved human cancer drug) alongside their standard cancer treatment, and reported remission, was published in 2025 and retracted by the journal in January 2026 — not because the clinical observations were found to be fabricated or incorrect, but because the lead author had an undisclosed financial conflict of interest (he offers paid clinical services related to fenbendazole cancer treatment), which the journal's editor concluded would have affected how the work should have been interpreted.

What This Doesn't Mean

This is NOT evidence that fenbendazole treats cancer. No clinical trial has ever tested this question in humans; this was an uncontrolled case series of three patients who were ALSO receiving standard cancer treatment at the same time, so the case series could never have established that fenbendazole caused their outcomes even before its retraction. The retraction itself means this paper is no longer valid, citable evidence for any claim at all — readers encountering this claim online should know the paper it is based on has been withdrawn.

Why It Matters

This is exactly the kind of viral "miracle cure" claim that is NOT scientifically established and that CancerDiscoveries exists to check against its actual, current source status. It is a widely-shared claim traced back to a real, once-peer-reviewed paper that has since been formally retracted, reported here with the precise, easy-to-misread distinction between "retracted for undisclosed conflict of interest" and "retracted because the data was proven false" stated plainly rather than blurred.

Promise & Proof

Proof — strength of the evidence 1 / 5

Base score from evidence stage: Early Human.
Study design (Case series / case report) is unusually weak for the claimed human evidence stage.

Promise — potential significance if later evidence holds up 4 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.
An early-stage finding (preclinical or early human) that already shows at least one concrete signal of significance above.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Three adult patients with stage IV cancers (breast, prostate, and melanoma) who self-administered fenbendazole, an over-the-counter veterinary dewormer with no FDA approval for any human use, alongside their own separately-received standard cancer treatment, as described in a since-retracted case series. (Adults)

Fenbendazole is not an approved or studied human cancer treatment; self-administering an unapproved veterinary drug alongside cancer treatment carries unknown risks and potential drug interactions that have never been formally studied in humans. This record should not be read, shared, or excerpted as encouragement to try fenbendazole for cancer.

Full evidence details

Study design: Case series / case report
Sample size: 3

Funding & Conflicts

The retraction itself was prompted by the original case series' lead author's undisclosed financial interest — he offers paid clinical services related to fenbendazole cancer treatment — as stated directly in the retraction notice cited below.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients" (Case Reports in Oncology) (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] 10.1159/000549387 Load-bearing source DOI 10.1159/000549387, PMID 41574240
Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients" (Case Reports in Oncology). DOI 10.1159/000549387, PMID 41574240.

Additional context

Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients (Case Reports in Oncology) — RETRACTED (opens in a new tab) (Peer-reviewed paper) [Peer-reviewed] [Retracted] 10.1159/000546362 DOI 10.1159/000546362, PMID 40605964
Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients (Case Reports in Oncology) — RETRACTED. DOI 10.1159/000546362, PMID 40605964.

Why Should I Trust This?

1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13